Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.vivanzabiosciences.com | |
Market Cap | 44.64 Cr. | |
Enterprise Value(EV) | 52.50 Cr. | 2023-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.25 | Trailing Twelve Months Ending 2023-06 |
Price-Earning Ratio (PE) | 43.81 | Trailing Twelve Months Ending 2023-06 |
Industry PE | 50.40 | Trailing Twelve Months Ending 2023-06 |
Book Value / Share | 1.15 | Trailing Twelve Months Ending 2023-06 |
Price to Book Value | 9.74 | Calculated using Price: 11.16 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 4.00 Cr. | 40,000,000 Shares |
FaceValue | 1 | |
About Vivanza Biosciences Ltd. | ||
The company is engaged in the business of business of Pharmaceutical Products. |
1 Day |
|
-1.93% |
1 Week |
|
-5.82% |
1 Month |
|
+1.55% |
3 Month |
|
+41.62% |
6 Month |
|
-43.47% |
1 Year |
|
-28.00% |
2 Year |
|
-16.72% |
5 Year |
|
+226.32% |
10 Year |
|
+310.29% |
8 years | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | -242.60 | -17.54 | 5.66 | -12.56 | -6.46 | 2.41 | 10.01 | 15.78 | |
Return on Capital Employed (%) | -11.38 | -10.82 | 12.73 | -0.40 | 5.74 | 17.11 | 12.25 | 10.91 | |
Return on Assets (%) | -9.49 | -7.99 | 2.37 | -4.15 | -1.75 | 0.72 | 2.77 | 3.15 |
Particulars | 8 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Shh. Funds | 0 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | |
Non Curr. Liab. | 0 | 1 | 1 | 0 | 3 | 1 | |||
Curr. Liab. | 1 | 3 | 6 | 7 | 9 | 5 | 9 | 17 | |
Minority Int. | |||||||||
Equity & Liab. | 1 | 7 | 10 | 11 | 12 | 8 | 16 | 22 | |
Non Curr. Assets | 1 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |
Curr. Assets | 0 | 4 | 7 | 8 | 9 | 5 | 12 | 20 | |
Misc. Exp. not W/O | |||||||||
Total Assets | 1 | 7 | 10 | 11 | 12 | 8 | 16 | 22 |
Particulars | 9 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-06 Rs. Cr. TTM |
Net Sales | 3 | 6 | 3 | 10 | 10 | 10 | 18 | 25 | ||
Other Income | 0 | 1 | 1 | 1 | 0 | 0 | ||||
Total Income | 4 | 6 | 3 | 10 | 10 | 11 | 18 | 25 | ||
Total Expenditure | 0 | -4 | -6 | -3 | -10 | -10 | -10 | -17 | -24 | |
PBIDT | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Depreciation | 0 | 0 | ||||||||
Taxation | 0 | 0 | 0 | 0 | ||||||
Exceptional Items | ||||||||||
PAT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
Minority Interest | ||||||||||
Share Associate | ||||||||||
Other Related Items | ||||||||||
Consolidated Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Particulars | 8 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | -2 | 0 | 1 | 3 | -3 | 2 | -1 | ||
Cash Fr. Inv. | 2 | 0 | |||||||
Cash Fr. Finan. | 0 | -1 | -1 | -3 | 2 | -2 | 1 | ||
Net Change | 0 | -1 | 0 | 0 | 0 | 0 | 0 | ||
Cash & Cash Eqvt | -2 | -3 | -3 | -3 | -3 | 0 | 0 |
Fri, 01 Sep 2023
Revised Outcome Of The Board Meeting For Quarter Ended June 30 2023 Revised Outcome of the Board Meeting for Quarter ended June 30 2023. |
Fri, 11 Aug 2023
Regulation 47 For Publication Of Financial Results For The Quarter Ended 30Th June 2023 Regulation 47 of SEBI LODR Publication of Financial Results for the Quarter ended 30th June 2023 |
Thu, 10 Aug 2023
Board Meeting Outcome for Outcome Of The Board Meeting For The Unaudited Standalone And Consolidate Financial Results For The Quarter Ended June 30 2023. Board at its meeting held today i.e.: 10.08.2023 has upon review by audit committee has considered and approved the unaudited standalone and consolidate financial results for the quarter ended June 30 2023. |
Tue, 26 Sep 2023 |
|
|
|
|
|